Visualization of Eluvia Drug-Eluting Stent and Ranger Drug-Coated Balloon.
TAKE THE FIGHT TO PAD

Exceptional choice.
Exceptional outcomes.

Vascular Surgery / Drug-Eluting Therapies / Overview

 

 

A bold step forward.

Boston Scientific is committed to advancing science in the fight against PAD by boldly innovating with next-generation, drug-eluting technology. Backed by Level-1 Randomized Controlled Trials, our proven exceptional results put the power of choice in the hands of those who make it happen. Together, we can save more limbs and help more people walk without pain.

Eluvia DES and Ranger DCB video

Healthcare professional in white coat in mid-conversation.

Two head-to-head trials.
Zero doubt.

Bold is being the first company to conduct Level-1 head-to-head comparative effectiveness trials directly comparing drug-eluting technologies. And we did it twice.

Eluvia DES Clinical Trials ›
Ranger DCB Clinical Trials ›

Drug-Eluting Technologies

 
Visualization of Eluvia Drug-Eluting Stent, with drug emanating from it.

Eluvia™ Drug-Eluting Vascular Stent System

Eluvia DES is designed with sustained release to match the restenotic process of the SFA, and has demonstrated superior primary patency at 1-Year against bare metal stents in EMINENT2 and Zilver PTX in IMPERIAL3. Eluvia DES delivers superior results.

Learn more about Eluvia DES

Visualization of Ranger Drug-Coated Balloon, with drug emanating from it.

Ranger™ Drug-Coated Balloon

Ranger DCB is built on the physician preferred Sterling™ 0.014”/0.018" balloon platform4 with the lowest tip entry profile of any SFA DCB5 and backed by clinical results which demonstrate consistent near 90% patency at 1-Year6 and exceptional outcomes at 2 years7. Ranger DCB delivers like nothing else.

Learn more about Ranger DCB

1. 88.4% K-M Primary Patency in the COMPARE Head-to-Head RCT. 1-Year Results published in the European Heart Journal. doi.org/10.1093/eurheartj/ehaa049. 89.8% K-M Primary Patency in the RANGER II SFA RCT.1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021. 92.1% K-M Primary Patency in the IMPE­RIAL Head-to-Head RCT. 1-Year Results published in The Lancet. https:/ /doi.org/10.1016/50140-6736(18}32262-1.
2. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. 1-Year Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).
3. IMPERIAL Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against Cook Medical’s Zilver™ PTX™ Stent, single-blind, non-inferiority design; independent core lab adjudication. Superiority determined in a post hoc analysis that was specified prior to unblinding. 1-Year Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value = 0.0144).
4. DRG data, CY 2020, 0.018" PTA Balloons.
5. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
6. 88.4% K-M Primary Patency in the COMPARE Head-to-Head RCT. 1-Year Results published in the European Heart Journal. doi.org/10.1093/eurheartj/ehaa049. 89.8% K-M Primary Patency in the RANGER II SFA RCT.1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021.
7. RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD. VIVA 2021. Highest 2- year primary patency based on 2-Year Kaplan-Meier estimates reported for Ranger II SFA, IN.PACT SFA, ILLUMENATE and LEVANT II including PTA arms.
Woman subtly smiling and looking to the side, with picnic and house behind.


ELEGANCE PATIENT REGISTRY

Addressing inequities in the treatment of Peripheral Artery Disease


The ELEGANCE Registry is a post-market clinical study with aims to expand the body of clinical evidence on the outcomes of patients diagnosed with peripheral artery disease — particularly those who identify as female and people of color — after being treated with a Boston Scientific drug-eluting device.
Learn More ›
Background image of surgical area and healthcare providers' hands.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Explore Resources ›
Background image of healthcare providers' hands using medical equipment.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Sign Up Today ›
take the fight to pad
Top